CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Delcath Systems Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Delcath Systems Inc
566 Queensbury Avenue
Phone: (518) 743-8892p:518 743-8892 QUEENSBURY, NY  12804  United States Ticker: DCTHDCTH

Business Summary
Delcath Systems, Inc. is an interventional oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it has been used in the conduct of percutaneous hepatic perfusion procedures at medical centers to treat a range of cancers of the liver.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes-Yes-

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board John R.Sylvester 59 2/16/2023 7/24/2019
Chief Executive Officer, Director Gerard J.Michel 59 10/1/2020 10/1/2020
Chief Operating Officer Martha S.Rook 53 3/18/2024 3/18/2024
10 additional Officers and Directors records available in full report.

Business Names
Business Name
DCTH
DCTHD
Delcath Holdings Limited
5 additional Business Names available in full report.

General Information
Number of Employees: 76 (As of 3/18/2024)
Outstanding Shares: 22,922,728 (As of 3/19/2024)
Shareholders: 57
Stock Exchange: NASD
Federal Tax Id: 061245881
Fax Number: (212) 489-2102
Email Address: info@delcath.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024